Media

AltaCorp Expands Research Coverage of Cannabis

Oct 03, 2018

AltaCorp Capital Inc. (AltaCorp), a leading capital markets firm, is pleased to announce the addition of David Kideckel as a Managing Director on the Equity Research Team, covering Healthcare and Life Sciences. Kideckel brings almost 20 years of health-related experience to this position and will be based in the firm's Toronto office.

"The cannabis sector continues to evolve rapidly as Canada moves toward legalization,” says Jon Horsman, AltaCorp Chairman & CEO. “With the development of cannabinoid applications in the medical industry, David's vast knowledge and direct experience in healthcare and biotechnology with both public and private companies make him a significant asset for our clients. Kideckel’s specialized background is a differentiating factor that will help investors and corporate clients navigate the complex business and regulatory environment that this new industry will face."

Prior to joining AltaCorp, Kideckel was the director of Healthcare & Biotechnology, Institutional Equity Research, at Beacon Securities Ltd. He has also held senior positions at various pharmaceutical and medical device companies, including Alexion Pharmaceuticals, OtoSim Inc., and Johnson & Johnson.

Kideckel graduated from the University of Winnipeg with a Bachelor of Science and Bachelor of Arts in neuropsychology. He went on to earn a Master of Science from McMaster University, a PhD in neuroscience from the Institute of Medical Science at the University of Toronto, and a Master of Business Administration from the Rotman School of Management, also at the University of Toronto.

"David's unique background will combine healthcare and business insights, and will be invaluable to AltaCorp's growing portfolio of cannabis and life sciences clients," says Nick Lupick, AltaCorp Head of Research. "This year, AltaCorp has raised or advised on over $2 billion of transactions in this sector, so David is an important addition to our team. His expertise will add another dimension to our analysis, turning insights into actionable investment opportunities for our clients."

Media inquiries:
Brenda Hanchar
403-539-8620 | 403-519-2220